🇺🇸 Milrinone Lactate in United States

285 US adverse-event reports

Marketing authorisations

FDA

  • Status: approved

FDA

  • Application: ANDA211671
  • Marketing authorisation holder: MEITHEAL
  • Status: approved

FDA

  • Application: ANDA219170
  • Marketing authorisation holder: CAPLIN
  • Status: approved

FDA

  • Application: ANDA216373
  • Marketing authorisation holder: SHANDONG
  • Status: approved

FDA

  • Application: ANDA090038
  • Marketing authorisation holder: HIKMA FARMACEUTICA
  • Status: approved

FDA

  • Application: ANDA075834
  • Marketing authorisation holder: BAXTER HLTHCARE
  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 93 reports (32.63%)
  2. Death — 63 reports (22.11%)
  3. Supraventricular Tachycardia — 30 reports (10.53%)
  4. Cardiac Failure — 17 reports (5.96%)
  5. Hypotension — 17 reports (5.96%)
  6. Allergic Myocarditis — 16 reports (5.61%)
  7. Renal Failure — 14 reports (4.91%)
  8. Ventricular Tachycardia — 13 reports (4.56%)
  9. Dyspnoea — 11 reports (3.86%)
  10. Off Label Use — 11 reports (3.86%)

Source database →

Milrinone Lactate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Cardiovascular approved in United States

Frequently asked questions

Is Milrinone Lactate approved in United States?

Yes. FDA has authorised it; FDA has authorised it; FDA has authorised it.

Who is the marketing authorisation holder for Milrinone Lactate in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.